Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines

Cancer

Volumn 122, Issue 13, 2016, Pages 2057-2066

  Burger, Emily A ^a,b   Lee, Kyueun ^a,c   Saraiya, Mona ^d   Thompson, Trevor D ^d   Chesson, Harrell W ^d   Markowitz, Lauri E ^d   Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c STANFORD UNIVERSITY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

health status disparities; human papillomavirus; neoplasms; vaccines

Indexed keywords

9 VALENT HUMAN PAPPILOMA VIRUS VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

AGE DISTRIBUTION; ANUS CANCER; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; EPIDEMIOLOGICAL DATA; ETHNIC DIFFERENCE; FEMALE; HEALTH DISPARITY; HUMAN; HUMAN PAPILLOMAVIRUS ASSOCIATED CANCER; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NEOPLASM; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK REDUCTION; SEX RATIO; SIMULATION; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VULVA CANCER; ETHNOLOGY; HEALTH CARE DISPARITY; MORTALITY; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; THEORETICAL MODEL; UNITED STATES; VIROLOGY;

FEMALE; HEALTHCARE DISPARITIES; HUMANS; MALE; MODELS, THEORETICAL; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES;

EID: 84975121949     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30007     Document Type: Article

References (20)

1. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105:175-201.
2. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov. 2014 Sub (1973–2012 varying)-Linked To County Attributes-Total US, 1969–2013 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2015.
3. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97:675-683.
4. Chen HY, Kessler CL, Mori N, Chauhan SP. Cervical cancer screening in the United States, 1993-2010: characteristics of women who are never screened. J Womens Health (Larchmt). 2012;21:1132-1138.
5. Elam-Evans L, Yankey D, Jeyarajah J, et al; Immunization Services Division, National Center for Immunization and Respiratory Diseases; Centers for Disease Control and Prevention (CDC). National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2013. MMWR Morb Mortal Wkly Rep. 2014;63:625-633.
6. Fisher H, Trotter CL, Audrey S, MacDonald-Wallis K, Hickman M. Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol. 2013;42:896-908.
7. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167-177.
8. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(suppl 5):F88-F99.
9. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359:821-832.
10. US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. SEER*Stat Database: NPCR and SEER Incidence—USCS file - 1999-2011.
11. Saraiya M, Unger ER, Thompson TD, et al. US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. J Natl Cancer Inst. 2015;107(6):djv086.
12. Centers for Disease Control and Prevention National Center for Health Statistics' National Vital Statistics System. National Vital Statistics Reports. 2014.
13. Pearcy JN, Keppel KG. A summary measure of health disparity. Public Health Rep. 2002;117:273-280.
14. Harper S, Lynch J. Methods for measuring cancer disparities: using data relevant to Healthy People 2010 cancer-related objectives. http://health-equity.pitt.edu/732/1/measuring_disparities.pdf. Accessed June 5, 2015.
15. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261-269.
16. Lasser KE, Himmelstein DU, Woolhandler S. Access to care, health status, and health disparities in the United States and Canada: results of a cross-national population-based survey. Am J Public Health. 2006;96:1300-1307.
17. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781-789.
18. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(suppl 5):F12-F23.
19. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958-966.
20. Brotherton JM, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observatio cohort of young women in Australia. Papillomavirus Res. 2015;1:59-73.